WHO Approves China’s Sinovac Covid Vaccine | Vaccines and Immunization


The World Health Organization has approved Xenoshine Covid-19 vaccine for emergency use. This is the second Chinese vaccine approved by the World Health Organization.

The United Nations health agency signed CoronaVac, a two-dose vaccine developed by the Beijing-based company that has been deployed in many countries around the world.

WHO Director-General Tedros Adhanom Ghebreyesus said at a press conference on Tuesday: “I am pleased to announce that the Sinovac-CoronaVac vaccine has been included in the WHO emergency use after it has been identified as safe, effective and quality assured List.”

“CoronaVac’s simple storage requirements make it ideal for resource-poor environments,” he added. “It is now vital to provide these life-saving tools to those who need them quickly.”

According to the WHO, the Emergency Use List (EUL) provides countries, funders, procurement agencies and communities with assurance that vaccines meet international standards.last month Sinopharm Group becomes China’s first vaccine Must be approved by the World Health Organization.

The organization also granted EUL status to vaccines produced by Pfizer/BioNTech, Moderna, Johnson & Johnson, and AstraZeneca vaccines produced in India, South Korea and the European Union. These vaccines are counted separately.

The WHO’s listing has paved the way for countries around the world to quickly approve and import vaccines for distribution, especially those countries that do not have their own international standards regulatory agencies.

It also opened the door for jabs to enter the Covax Global Vaccine Sharing Facility, which aims to provide equitable vaccination opportunities across the world, especially in poorer countries. Currently only some vaccines from AstraZeneca and Pfizer are passing the plan.

“The world urgently needs multiple Covid-19 vaccines to solve the huge global inequality of access,” said Mariangela Simao, WHO’s Assistant Director-General for Access to Health Products.

“We urge manufacturers to participate in the Covax facility, share their expertise and data, and contribute to the control of the pandemic.”

The agency said in a statement: “WHO recommends that the vaccine be used for adults 18 years of age and older, in two doses with an interval of 2 to 4 weeks.”

“Vaccine efficacy results show that the vaccine prevented symptomatic diseases in 51% of vaccinators, and prevented severe Covid-19 and hospitalization in 100% of the study population.”

Sinovac vaccine contains an inactivated form of coronavirus that does not cause disease. It also contains a substance that helps strengthen the immune response to vaccines.

After the vaccine is injected, the immune system recognizes the inactivated virus as a foreign virus and produces antibodies against it, then recognizes the active virus and protects the body from it.

Few people over 60 have participated in Kexing’s jab clinical trials. However, the WHO stated that the vaccine should not set an upper age limit because “there is no reason to believe that it has different safety in the older generation.”

According to AFP statistics, Sinovac jabs have been used in 22 regions around the world.apart from China, The countries that use Coxing include Chile, Brazil, Indonesia, Mexico, Thailand and Turkey.

Chinese Ambassador to Geneva Chen Xu said that CoronaVac’s EUL status has expanded the number of tools for the global fight against the pandemic.

He said in a tweet: “China will continue to cooperate with the international community to promote the availability and affordability of the Covid-19 vaccine, especially in developing countries.”


Source link

Recommended For You

About the Author: News Center